Iaso Therapeutics, a Michigan State University startup developing novel technologies for next-generation vaccines, recently closed the first tranche of the company’s $1.25M Series Seed Preferred round of financing.
Iaso Therapeutics Receives Grant from the National Science Foundation for Next-Generation Vaccine Researchjeff@orbit.digital2022-03-14T11:27:00-04:00
The nearly $1 million grant will fund vaccine delivery research targeting infectious diseases and cancer EAST LANSING, Mich., March 14, 2022 -- Iaso Therapeutics, a research program focused on the [...]
Iaso Therapeutics Awarded Competitive Grant from the National Institute of Allergy and Infectious Diseasesjeff@orbit.digital2022-02-11T13:57:41-05:00
Small Business Innovation Research Program Provides Seed Funding for R&D East Lansing, MI, 07/15/2021 – Iaso Therapeutics, INC. has been awarded a National Institute of Allergy and Infectious Diseases (NIAID) [...]
East Lansing, MI – Iaso has been selected to receive a $10k investment by the Michigan State University (MSU) Student Venture Capital Fund (MSU SVCF). This spring, Iaso participated in [...]